HotSpot Therapeutics to Present Additional Phase 1 Biomarker Data on Novel CBL-B Inhibitor HST-1011 at 2024 Society for Immunotherapy of Cancer Annual Meeting
Txylo.com/10289294

BOSTON, Oct. 4, 2024 ~ Journalist: HotSpot Therapeutics, Inc. has announced that they will be presenting additional Phase 1 clinical biomarker data for their investigational drug, HST-1011, at the 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting in Houston, Texas. The company is a biotechnology pioneer in the development of oral, small molecule allosteric therapies that target regulatory sites on proteins known as "natural hotspots."

The poster presentation will showcase the exploration of potential clinical biomarkers that correlate with signs of clinical activity in patients from the ongoing Phase 1 monotherapy dose-escalation study of HST-1011. Titled "Peripheral Blood and Tumor Gene Expression as Biomarkers and Potential Predictors of Clinical Outcome with HST-1011, an Oral CBL-B Inhibitor," the presentation will take place on Saturday, November 9th at 9:00 AM CT in Exhibit Halls A & B at the George R. Brown Convention Center.

More on Txylo.com

• Free PDF "My Higher Power"; Donations Print Books for Recovery
• Texas Children's Hospital and UT MD Anderson Announce $150 Million Gift from Kinder Foundation to Launch Kinder Children's Cancer Center
• Texas: Governor Abbott Signs Pro-Growth Business Legislation Into Law
• Texas: Governor Abbott Announces NTxBio Facility In Plano
• Colliers facilitates sale of The Offices at Telfair in Sugar Land

The abstract number for this presentation is 1310 and it will be part of a session that runs from 9:00 AM to 8:30 PM CT on November 9th. This announcement highlights HotSpot Therapeutics' commitment to advancing their innovative therapies and potential treatments for patients.

---

Show All News | Report Violation